ACTRN12611000568910尚未招募不适用
A Single and Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics SCH 900931 in Healthy Adult Japanese Subjects.
Schering-Plough Research Institute, a Division of Schering Corporation, a Subsidiary of Merck & Co., Inc0 个研究点目标入组 24 人开始时间: 2011年6月2日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •Healthy Japanese volunteers
排除标准
- •History of malignancy, Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C
研究者
相似试验
已完成
1 期
Multiple Dose Study of MK-6024 in Healthy Japanese Participantsonalcoholic steatohepatitisJPRN-jRCT2031210703Yoshiyuki Tanaka20
已完成
1 期
A single centre, double blind, randomised, parallel group, ascending single and multiple dose, safety and tolerability, pharmacokinetic and pharmacodynamic study of vaginal ointment in healthy women volunteersInfection - Sexually transmitted infectionsCervical neoplasiaCondyloma acuminatumACTRN12618000883213Zenith Technology Corp Ltd18
招募中
1 期
A Single- and Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Intravenous Doses of LY3002813Alzheimer DiseaseJPRN-jRCT2080223143Eli Lilly Japan K.K.
进行中（未招募）
不适用
A Safety Study of Mebendazole in Children 2 to 10 Years of AgeSoil-transmitted helminth (STH) infectionsMedDRA version: 17.1Level: LLTClassification code 10063126Term: WormsSystem Organ Class: 100000004862EUCTR2015-001226-42-Outside-EU/EEAJohnson & Johnson Pharmaceutical Research & Development, L.L.C.397
进行中（未招募）
2 期
A multicentre single arm study of carfilzomib-thalidomide-dexamethasone (CarTD) for newly diagnosed transplant-eligible multiple myeloma (MM) patients refractory to initial bortezomib-based induction therapyCancer - MyelomaMultiple MyelomaACTRN12615000934549Australiasian Leukaemia and Lymphoma Group50